Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GJB2 | P29033 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | PYGB | P11216 | 2/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.41 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.41 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | IGF2R | P11717 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30391777 | 0.93 | MAPK1 (0.53) | GJB2MAPK1MMP13PYGB | |
| SCHEMBL4298713 | 0.92 | MAPK1 (0.55) | GJB2MAPK1MMP13 | |
| SCHEMBL14506448 | 0.92 | MAPK1 (0.55) | GJB2MAPK1MMP13 | |
| SCHEMBL16092453 | 0.92 | MAPK1 (0.55) | GJB2MAPK1MMP13 | |
| SCHEMBL12141519 | 0.91 | GJB2 (0.44) | GJB2MAPK1MMP13LGALS8LGALS3 | |
| SCHEMBL17776426 | 0.91 | GJB2 (0.44) | GJB2MAPK1MMP13PYGBLGALS8 | |
| SCHEMBL17776036 | 0.90 | MAPK1 (0.45) | GJB2MAPK1MMP13LGALS8LGALS3 | |
| SCHEMBL16644847 | 0.90 | MAPK1 (0.45) | GJB2MAPK1MMP13LGALS8LGALS3 | |
| SCHEMBL19841402 | 0.90 | MMP13 (0.43) | GJB2MAPK1MMP13LGALS8LGALS3 | |
| SCHEMBL16644882 | 0.90 | MAPK1 (0.45) | GJB2MAPK1MMP13LGALS8LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9889205-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9884125-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20160303244-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160251407-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-09-01 | — | — | US | disclosed |
| US-9427475-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150105317-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME LLC | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105317-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | GJB2 3707/4885MAPK1 1090/4885MMP13 3215/4885 |
| US-20160251407-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | GJB2 4032/4885MAPK1 1013/4885MMP13 3498/4885 |
| US-20160303244-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | GJB2 3707/4885MAPK1 1090/4885MMP13 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.